Literature DB >> 12485681

A two-component modular approach for enhancing T-cell activation utilizing a unique anti-FcgammaRI-streptavidin construct and microspheres coated with biotinylated-antigen.

Mary C Walsh1, Jeffrey A Banas, Stanley P Mudzinski, Mark T Preissler, Robert F Graziano, Edmund J Gosselin.   

Abstract

The professional antigen presenting cell (APC) plays an essential role in the initiation and propagation of the acquired immune response. Thus, much work has been done in designing strategies that target vaccine antigen (Ag) to APC. Utilizing recombinant DNA technology, we have created a unique two-component system that delivers biotinylated Ag to the Fc gamma receptor type I (FcgammaRI) on APC. Our studies demonstrate that we can successfully engineer FcgammaRI-specific targeting element proteins that simultaneously bind both biotin and recognize FcgammaRI. Additionally, we are able to engineer biotinylated Ag, which form functional elements when adsorbed onto latex microspheres. Furthermore, the targeting and functional element components bind to each other and successfully form two-component immunogens. T-cell activation in response to targeted Ag-laden microspheres is 10- to 100-fold greater than the response to the non-targeted Ag-laden microspheres. This enhancement is 100- to 1000-fold greater than the responses generated to soluble Ag. Thus, our results suggest that specific targeting of Ag-laden microspheres to FcgammaRI may significantly enhance the adjuvant properties of microparticulate delivery systems. Further development of this system may help to elucidate the mechanisms involved in generating enhanced responses to APC-targeted vaccines and significantly advance vaccine technology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12485681     DOI: 10.1016/s1389-0344(02)00089-8

Source DB:  PubMed          Journal:  Biomol Eng        ISSN: 1389-0344


  7 in total

1.  Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.

Authors:  Constantine Bitsaktsis; Bibiana V Iglesias; Ying Li; Jesus Colino; Clifford M Snapper; Susan K Hollingshead; Giang Pham; Diane R Gosselin; Edmund J Gosselin
Journal:  Infect Immun       Date:  2011-12-12       Impact factor: 3.441

2.  Production of genetically engineered biotinylated interleukin-2 and its application in a rapid nonradioactive assay for T-cell activation.

Authors:  Robert A Jordan; Mark T Preissler; Jeffrey A Banas; Edmund J Gosselin
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

Review 3.  Current understanding of interactions between nanoparticles and the immune system.

Authors:  Marina A Dobrovolskaia; Michael Shurin; Anna A Shvedova
Journal:  Toxicol Appl Pharmacol       Date:  2015-12-29       Impact factor: 4.219

Review 4.  PLA micro- and nano-particles.

Authors:  Byung Kook Lee; Yeonhee Yun; Kinam Park
Journal:  Adv Drug Deliv Rev       Date:  2016-06-01       Impact factor: 15.470

5.  Construction and immunogenicity of a new Fc-based subunit vaccine candidate against Mycobacterium tuberculosis.

Authors:  Abdollah Kebriaei; Mohammad Derakhshan; Zahra Meshkat; Mohammad Reza Akbari Eidgahi; Seyed Abdolrahim Rezaee; Hadi Farsiani; Arman Mosavat; Saman Soleimanpour; Kiarash Ghazvini
Journal:  Mol Biol Rep       Date:  2016-06-01       Impact factor: 2.316

6.  Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis.

Authors:  Deepak B Rawool; Constantine Bitsaktsis; Ying Li; Diane R Gosselin; Yili Lin; Nitin V Kurkure; Dennis W Metzger; Edmund J Gosselin
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

7.  Active immunity induced by passive IgG post-exposure protection against ricin.

Authors:  Charles Chen Hu; Junfei Yin; Damon Chau; John W Cherwonogrodzky; Wei-Gang Hu
Journal:  Toxins (Basel)       Date:  2014-01-21       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.